Healthcare Industry News:  Teva Pharma 


 News Release - December 11, 2006

Synerx Pharma Announces Teva Marketing Partnership

NEWTOWN, Pa.--(HSMN NewsFeed)--Synerx Pharma, LLC announced today that it has entered into a definitive agreement with Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA ) whereby Synerx will develop and secure FDA approval for a number of undisclosed products. Teva will market and distribute these products in the United States under license from Synerx, upon receiving final FDA approval.

Synerx Pharma currently has ten products under various stages of development. These development efforts encompass four different dosage form categories and five exclusive Active Pharmaceutical Ingredient agreements with multiple manufacturers. The Company anticipates having 5 ANDA's filed with FDA by the close of 2006.

About Synerx Pharma, LLC:

Synerx Pharma LLC is a privately held corporation located in historic Bucks County, Pennsylvania. Established in January 2004, the company focuses primarily on cost-effective generic products aimed at meeting underserved consumer needs, particularly those involving some combination of barriers to entry.

Synerx Pharma commercializes its products through the aggressive establishment of development, manufacturing, and supply partnerships bringing quality, value-added products to the marketplace. Synerx partners with high quality contract development and manufacturing organizations, leveraging their diverse capabilities in a variety of dosage forms and delivery technologies.

Synerx Pharma welcomes inquiries concerning partnership opportunities. Inquiries from companies outside the U.S. regarding the commercialization of their products and technologies in the U.S. marketplace are also encouraged.

Source: Synerx Pharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.